Hospital Wanita Dan Kanak-Kanak Sabah, Malaysia
Dr. Sucharit Pongprakyun obtained his medical degree from Universiti Putra Malaysia (UPM) in 2004. He subsequently pursued a postgraduate degree in Clinical Oncology in Universiti Malaya (UM). He previously worked at the National Cancer Institute (IKN). Currently, he serves as a clinical oncologist at the Nuclear Medicine & Radiotherapy Centre of Sabah Women and Children Hospital (Hospital Likas) in Kota Kinabalu, Sabah. He is actively involved in clinical trials and clinical teaching for medical officers. His area of interest includes head and neck, lung, breast and colorectal cancer.
Metastatic Gastric Cancer – Molecular & Clinical Updates
Metastatic gastric cancer remains one of the more challenging cancers to treat. According to the GLOBOCAN 2018 data, it is the third most common cause of cancer death worldwide. In Malaysia, it is the 8th most common cancer among males and 10th most common cancer among females but ranks as the 6th most common cause of cancer death for 2018. It has been reported that majority of cases in Malaysia are detected at an advanced stage. Early detection followed by the appropriate treatment would help to improve the survival of patients. Chemotherapy has been used as the mainstay of treatment for many decades in advanced/metastatic disease. The emergence of newer class of drugs such as monoclonal antibodies and immunotherapy have broaden the scope of treatment options available. However, the survival rates although improved with the presence of newer agents, have remained dismal. Specific biomarkers discovered such as HER2 has allowed a more targeted-based treatment to be used in subtypes which harbor this biomarker. It is important to explore further the role of biomarkers in gastric cancer and to be aware of biomarkers currently been used in clinical practice, in clinical trials and in various stages of research.